Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Immunochemotherapy Followed by Concurrent Immuno-Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Cancer
NCT06173986Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Primary endpoints: Progression-free survival at 60 months and Treatment completion rate at 1 year. Started Jan 2023; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06173986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173986.